Drug
Krn23
Krn23: highest development phase Post-Market, developed by Kyowa Kirin. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| KRN23 NCT05357573 | Post-Market | Tumor-Induced Osteomalacia (TIO) |
Latest
No recent events.
Follow Krn23 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.